LifeStance Health Group, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the supplied filing text does not provide standalone fourth-quarter results.
Business context
LifeStance operates an outpatient mental-health platform offering in-person and virtual care through subsidiaries and supported practices. At year-end, it employed 6,645 clinicians across 33 states and operated 575 centers. In 2023, clinicians treated more than 880,000 unique patients in approximately 6.9 million visits. Revenue is principally fee-for-service; 91% came from commercial in-network payors, 4% from government payors, 4% from self-pay, and 1% from non-patient services.
Financial and operating performance
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Revenue | $1,055.7 million | $859.5 million | Up 23% |
| Operating loss | $(189.1) million | $(210.2) million | Improved by $21.0 million |
| Net loss | $(186.3) million | $(215.6) million | Improved by $29.3 million |
| Adjusted EBITDA | $59.0 million | $52.7 million | Up $6.4 million; non-GAAP |
| Center Margin | $302.1 million | $237.0 million | Up $65.1 million; non-GAAP |
| Cash from operating activities | $(16.9) million | $52.8 million | Declined $69.7 million |
| Cash and cash equivalents | $78.8 million | $108.6 million | Down $29.8 million |
| Long-term debt principal | $289.5 million | $234.0 million | Up $55.5 million |
Calculated from reported figures, operating-loss margin was approximately (17.9%) in 2023 versus (24.5%) in 2022; net-loss margin was approximately (17.6%) versus (25.1%). Adjusted EBITDA margin was approximately 5.6% versus 6.1%. Center Margin is not a measure of company-wide profitability and excludes general and administrative expenses and depreciation and amortization.
Patient visits increased by 1.1 million, or 20%, year over year, supported by clinician growth, productivity, and the full-year contribution of prior acquisitions. Management also cited modest payor rate increases. Center costs rose 21% to $753.6 million, while G&A rose 9% to $410.8 million. Stock-based compensation fell to $99.4 million from $187.4 million, partly offsetting higher salaries, legal and other operating costs.
Cash used in investing activities was $60.3 million, including $40.5 million of property and equipment purchases and $19.8 million for acquisitions. Financing activities provided $47.4 million, primarily from debt borrowings. Current assets were $225.7 million and current liabilities $202.9 million at year-end (approximately 1.11 current ratio). The company reported $269.5 million of undiscounted future minimum operating lease payments.
Material changes, outlook and commentary
- Revenue growth moderated to 23% from 29% in 2022. Despite higher revenue and improved GAAP losses, operating cash flow turned negative.
- Management attributed the operating cash use in part to the net loss and working-capital movements, including payments for the shareholder class-action settlement and related legal costs. The company paid substantially all of the settlement and related costs during 2023.
- LifeStance recorded $11.0 million in real-estate optimization and restructuring charges, including impairment and disposal costs, as it closed or exited underoccupied offices in response to greater virtual-care use. It expects to continue optimizing its footprint in 2024.
- Management expects growth to be driven by clinician recruiting, de novo centers, patient visits, and virtual-care capacity. It expects center costs to increase in the short to medium term as it invests in expansion, and G&A to rise in the foreseeable future with growth initiatives and public-company infrastructure. The filing text does not provide a clear numeric revenue or earnings forecast.
- At December 31, 2023, $289.5 million of principal was outstanding under the 2022 Credit Agreement; the company reported compliance with its financial covenants. A rate swap hedged 94.5% of the term loan previously exposed to SOFR risk and matures in September 2025. Management said cash and cash equivalents should fund operating and capital needs for at least 12 months from the financial statements’ issuance date, while noting this assessment depends on assumptions and actual cash needs.
- The 2023 results include a $50 million net-of-insurance shareholder securities-class-action settlement expense. The court approved the settlement in January 2024. Two employee compensation-related class/collective actions and a website privacy-related class action remained ongoing; the company had not recorded material accruals for these matters and said any loss range was not estimable.
Risks and controls
Key business risks include payor rate reductions or loss of network access, dependence on major payors (UnitedHealthcare and Elevance represented 19% and 13% of 2023 revenue), clinician recruitment and retention, competition, and the heavily regulated healthcare environment. Other material risks include corporate-practice-of-medicine and fee-splitting challenges involving supported practices, evolving telehealth rules, privacy and cybersecurity events, lease commitments, and debt service and covenant restrictions.
Management and the auditor concluded that internal control over financial reporting was ineffective at December 31, 2023 because of material weaknesses in the control environment, accounting policies and controls, and IT general controls. The auditor’s opinion on the financial statements was unqualified, but its opinion on internal control was adverse. Remediation work was ongoing; the weaknesses were not considered remediated. Management also concluded disclosure controls and procedures were ineffective. The auditor identified valuation of patient accounts receivable as a critical audit matter; receivables, net, were $125.4 million at year-end.
Important facts for investors to verify
- Whether clinician hiring, productivity, visit growth, and reimbursement rates sustain revenue growth without further deterioration in operating cash flow.
- Cash collection and receivables quality, including the assumptions behind the $125.4 million net receivable balance and exposure to the two largest payors.
- Progress in remediating material weaknesses, including whether controls operate effectively for a sufficient period and whether further reporting issues emerge.
- Cash requirements for debt, leases, capital spending, and restructuring; covenant headroom and interest exposure should performance weaken.
- Final costs and outcomes of the employee and privacy litigation, and any further effects of real-estate closures and the shift toward virtual care.